pharma M&A

High inflation and interest rates along with an uncertain business environment have disincentivised investment. The focus shifts…

Veeda expands its reach to major geographies and adds capabilities of late-stage clinical trial execution with strong focus on…

It is slated to become operational in the year 2024

While the big names are in the news, we could see a similar consolidation among pharma MSMEs which might not hit the headlines 

The acquisition significantly enhances Amneal’s injectables manufacturing infrastructure, capabilities, and capacity to support…

Chandru Chawla, a pharma veteran, opines that Biocon and SII coming together is a milestone event in the evolution of Indian…

Deal value decreased by 16.9 per cent in May 2021, compared to April 2021

Hikma had said in January that it was planning to buy those assets

Arvind Sharma, Partner, Shardul Amarchand Mangaldas & Co informs that the extant regulatory regime for FDI in brownfield…